Navigation Links
New ALR-LRI Collaboration to Accelerate New Treatments for Lupus

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Today, the Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) announced a trailblazing cooperative project to speed up the identification and availability of new treatments for lupus. Details of this new effort focused on identifying new treatments for lupus from among those that have been approved for other human conditions can be found at

With only one drug approved for lupus in over 50 years and serious side effects of existing treatments, there is a critical need for new therapies to treat and stop progression of this dangerous autoimmune disease. Despite the advance of new science, the overall pace of drug development in lupus has been slow. The ALR and LRI believe it is possible to identify therapies more quickly and are taking a proactive role to drive this process.

Developing New Lupus Treatments
An initial scan of all of the drugs and treatments available for human use has found approximately 70 existing therapies that have been approved for other conditions -- multiple sclerosis, rheumatoid arthritis, transplant rejection or cancer -- that potentially could be used to treat lupus. The new collaborative project will produce a comprehensive evidence-based analysis to fully document and prioritize each as a potential lupus therapy based on mechanism of action, safety profile, availability, feasibility to carry out a trial in lupus, and likelihood to succeed. A panel of academic and industry experts will review the database and prioritize potential therapies, and approximately 20 candidates are expected to emerge for further study in small focused science-rich clinical trials.

The study process and analysis will be fully transparent throughout; the priority list of candidate drugs and treatments will be made widely available for use across the lupus community to advance testing of potential new treatments in lupus.

"The urgent needs of lupus patients for safer and more effective treatments is the impetus for this newly energized, aggressive approach to drug development," said Margaret Dowd, President and CEO of the Lupus Research Institute.

"We are excited about this collaboration between our two organizations and believe that by combining resources we will be able to accelerate the development of new lupus treatments," Alliance for Lupus Research President Kenneth M. Farber commented.

Scientific coordinator of this project, Peter Lipsky, MD noted, "By maintaining complete objectivity, depending on scientific analysis and pre-set rules of prioritization, and engaging the academic, clinical and pharmaceutical communities in a transparent manner, this process should accelerate the identification of new therapeutic candidates with real potential to improve lives of patients with lupus and contribute to de-risking the process of developing new treatments for this disease."

Developer of scientific content, Amrie Grammer, PhD commented, "The project is eager to hear from all with expertise and/or interest in solving the seemingly insurmountable problem of developing new therapies for lupus, which can manifest itself in nearly every organ and body system. We are open and ready to assess suggested therapies."

About Lupus
Lupus is a chronic autoimmune disease that causes inflammation and tissue damage to any organ system in the body. The health effects of lupus include heart attacks, strokes, seizures, organ failure, and possible death.

About the ALR
The Alliance for Lupus Research (ALR) is a national voluntary health organization dedicated to finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE, or lupus), a debilitating autoimmune disease. The organization is based in New York City and chaired by Robert Wood Johnson IV, a member of the founding family of Johnson & Johnson. Since its founding in 1999, the ALR has given more money to lupus research than any non-governmental agency in the world. The board of directors funds all administrative and fundraising costs, allowing one hundred percent of all donations to go directly to support research programs. More information can be found at

About the LRI
The Lupus Research Institute (LRI), the leading private supporter of novel research in lupus, pioneers discovery and champions scientific creativity as it demonstrates the power of innovation to propel scientific discovery in this complex autoimmune disease. Founded by families and shaped by leading scientists, the Institute has generated $170 million in novel lupus research, delivering many of the decade's most pivotal discoveries, transforming treatment and advancing toward prevention and a cure. 

With its National Patient Coalition of regional lupus organizations, the Lupus Research Institute improves patient care by promoting research awareness, education and advocacy as it drives to A Life Without Lupus. For more information, visit

SOURCE The Lupus Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMTC announces Physician Collaboration Platform ("PCP") Upgrade: A cloud-based telehealth solution for improved collaboration, access and performance
2. Genarts 18th Annual Film Festival Announces Collaboration With The Partnership At For #endmedicineabuse Project
3. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
4. MinuteClinic Signs Clinical Collaboration with Baptist Health Care for Clinic Locations in Three-County Region of Northwest Florida
5. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
6. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
7. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
8. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
9. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
10. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
11. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
Breaking Medicine News(10 mins):